272 related articles for article (PubMed ID: 33381924)
1. Plasma growth differentiation factor 15: a novel tool to detect early changes of hereditary transthyretin amyloidosis.
Okada M; Misumi Y; Masuda T; Takashio S; Tasaki M; Matsushita H; Ueda A; Inoue Y; Nomura T; Nakajima M; Yamashita T; Shinriki S; Matsui H; Tsujita K; Ando Y; Ueda M
ESC Heart Fail; 2021 Apr; 8(2):1178-1185. PubMed ID: 33381924
[TBL] [Abstract][Full Text] [Related]
2. Non-invasive detection and differentiation of cardiac amyloidosis using
Takasone K; Katoh N; Takahashi Y; Abe R; Ezawa N; Yoshinaga T; Yanagisawa S; Yazaki M; Oguchi K; Koyama J; Sekijima Y
Amyloid; 2020 Dec; 27(4):266-274. PubMed ID: 32722948
[TBL] [Abstract][Full Text] [Related]
3. Performance of
Guo H; Wu S; Xiang X; Wang S; Fang Z; Ye Q; Zou Y; Wang Y; Peng D; Ma X
Ann Nucl Med; 2024 Apr; 38(4):288-295. PubMed ID: 38252229
[TBL] [Abstract][Full Text] [Related]
4. Neurofilament light chain, a biomarker for polyneuropathy in systemic amyloidosis.
Louwsma J; Brunger AF; Bijzet J; Kroesen BJ; Roeloffzen WWH; Bischof A; Kuhle J; Drost G; Lange F; Kuks JBM; Gans ROB; Hazenberg BPC; Nienhuis HLA
Amyloid; 2021 Mar; 28(1):50-55. PubMed ID: 32883119
[TBL] [Abstract][Full Text] [Related]
5. Skin amyloid deposits and nerve fiber loss as markers of neuropathy onset and progression in hereditary transthyretin amyloidosis.
Leonardi L; Adam C; Beaudonnet G; Beauvais D; Cauquil C; Not A; Morassi O; Benmalek A; Trassard O; Echaniz-Laguna A; Adams D; Labeyrie C
Eur J Neurol; 2022 May; 29(5):1477-1487. PubMed ID: 35100482
[TBL] [Abstract][Full Text] [Related]
6. Dual-Echo Turbo Spin Echo and 12-Echo Multi Spin Echo Sequences as Equivalent Techniques for Obtaining T2-Relaxometry Data: Application in Symptomatic and Asymptomatic Hereditary Transthyretin Amyloidosis as a Surrogate Disease.
Poncelet A; Weiler M; Hegenbart U; Sam G; Schönland S; Purrucker JC; Hayes JM; Hund E; Bendszus M; Heiland S; Kollmer J
Invest Radiol; 2022 May; 57(5):301-307. PubMed ID: 34839307
[TBL] [Abstract][Full Text] [Related]
7. A natural history analysis of asymptomatic
Coelho T; Conceição I; Waddington-Cruz M; Keohane D; Sultan MB; Chapman D; Amass L;
Amyloid; 2022 Dec; 29(4):228-236. PubMed ID: 35730447
[TBL] [Abstract][Full Text] [Related]
8. Monitoring of asymptomatic family members at risk of hereditary transthyretin amyloidosis for early intervention with disease-modifying therapies.
Ueda M; Sekijima Y; Koike H; Yamashita T; Yoshinaga T; Ishii T; Ando Y
J Neurol Sci; 2020 Jul; 414():116813. PubMed ID: 32353608
[TBL] [Abstract][Full Text] [Related]
9. Serum neurofilament light chain: a promising early diagnostic biomarker for hereditary transthyretin amyloidosis?
Romano A; Primiano G; Antonini G; Ceccanti M; Fenu S; Forcina F; Gentile L; Inghilleri M; Leonardi L; Manganelli F; Obici L; Sabino A; Sciarrone MA; Tozza S; Vitali F; Luigetti M
Eur J Neurol; 2024 Jan; 31(1):e16070. PubMed ID: 37724995
[TBL] [Abstract][Full Text] [Related]
10. Hereditary transthyretin amyloidosis overview.
Manganelli F; Fabrizi GM; Luigetti M; Mandich P; Mazzeo A; Pareyson D
Neurol Sci; 2022 Dec; 43(Suppl 2):595-604. PubMed ID: 33188616
[TBL] [Abstract][Full Text] [Related]
11. Magnetic resonance neurography and diffusion tensor imaging of the sciatic nerve in hereditary transthyretin amyloidosis polyneuropathy.
Gasparotti R; Salvalaggio A; Corbo D; Agazzi G; Cacciavillani M; Lozza A; Fenu S; De Vigili G; Tagliapietra M; Fabrizi GM; Pareyson D; Obici L; Briani C
J Neurol; 2023 Oct; 270(10):4827-4840. PubMed ID: 37329346
[TBL] [Abstract][Full Text] [Related]
12. Sex-Related Risk of Cardiac Involvement in Hereditary Transthyretin Amyloidosis: Insights From THAOS.
Caponetti AG; Rapezzi C; Gagliardi C; Milandri A; Dispenzieri A; Kristen AV; Wixner J; Maurer MS; Garcia-Pavia P; Tournev I; Planté-Bordeneuve V; Chapman D; Amass L;
JACC Heart Fail; 2021 Oct; 9(10):736-746. PubMed ID: 34391735
[TBL] [Abstract][Full Text] [Related]
13. Real-world outcomes in non-endemic hereditary transthyretin amyloidosis with polyneuropathy: a 20-year German single-referral centre experience.
Ungerer MN; Hund E; Purrucker JC; Huber L; Kimmich C; Aus dem Siepen F; Hein S; Kristen AV; Hinderhofer K; Kollmer J; Schönland S; Hegenbart U; Weiler M
Amyloid; 2021 Jun; 28(2):91-99. PubMed ID: 33283548
[TBL] [Abstract][Full Text] [Related]
14. Characterization and natural history of different phenotypes in hereditary transthyretin amyloidosis: 40-year experience at a single Italian referral centre.
Caponetti AG; Sguazzotti M; Accietto A; Saturi G; Ponziani A; Giovannetti A; Massa P; Ruotolo I; Sena G; Zaccaro A; Parisi V; Bonfiglioli R; Guaraldi P; Gagliardi C; Cortelli P; Galie N; Biagini E; Longhi S
Eur J Prev Cardiol; 2024 May; 31(7):866-876. PubMed ID: 38204330
[TBL] [Abstract][Full Text] [Related]
15. Longitudinal analysis of serum neurofilament light chain levels as marker for neuronal damage in hereditary transthyretin amyloidosis.
Berends M; Brunger AF; Bijzet J; Kroesen BJ; Drost G; Lange F; Teunissen CE; In 't Veld S; Vrancken AF; Gans ROB; Hazenberg BPC; van der Zwaag PA; Nienhuis HLA
Amyloid; 2024 Jun; 31(2):132-141. PubMed ID: 38477065
[TBL] [Abstract][Full Text] [Related]
16. Biomarkers of axonal damage to favor early diagnosis in variant transthyretin amyloidosis (A-ATTRv).
González-Moreno J; Gragera-Martínez Á; Rodríguez A; Borrachero-Garro C; García-Garrido S; Barceló C; Manovel-Sánchez A; Ribot-Sansó MA; Ibargüen-González L; Gomila R; Muñoz-Beamud F; Losada-López I; Cisneros-Barroso E
Sci Rep; 2024 Jan; 14(1):581. PubMed ID: 38182630
[TBL] [Abstract][Full Text] [Related]
17. Cardiac [
Tingen HSA; Tubben A; Bijzet J; van den Berg MP; van der Meer P; Houwerzijl EJ; Muntinghe FLH; van der Zwaag PA; Glaudemans AWJM; Oerlemans MIFJ; Knackstedt C; Michels M; Hirsch A; Hazenberg BPC; Slart RHJA; Nienhuis HLA
Eur J Nucl Med Mol Imaging; 2024 Feb; 51(3):681-690. PubMed ID: 37843599
[TBL] [Abstract][Full Text] [Related]
18. Detailed clinical, physiological and pathological phenotyping can impact access to disease-modifying treatments in ATTR carriers.
Beauvais D; Labeyrie C; Cauquil C; Francou B; Eliahou L; Not A; Echaniz-Laguna A; Adam C; Slama MS; Benmalek A; Leonardi L; Rouzet F; Adams D; Algalarrondo V; Beaudonnet G
J Neurol Neurosurg Psychiatry; 2024 May; 95(6):489-499. PubMed ID: 37875336
[TBL] [Abstract][Full Text] [Related]
19. Neurofilament Light Chain as a Biomarker of Hereditary Transthyretin-Mediated Amyloidosis.
Ticau S; Sridharan GV; Tsour S; Cantley WL; Chan A; Gilbert JA; Erbe D; Aldinc E; Reilly MM; Adams D; Polydefkis M; Fitzgerald K; Vaishnaw A; Nioi P
Neurology; 2021 Jan; 96(3):e412-e422. PubMed ID: 33087494
[TBL] [Abstract][Full Text] [Related]
20. Extracellular Vesicles Contribute to the Metabolism of Transthyretin Amyloid in Hereditary Transthyretin Amyloidosis.
Yamaguchi H; Kawahara H; Kodera N; Kumaki A; Tada Y; Tang Z; Sakai K; Ono K; Yamada M; Hanayama R
Front Mol Biosci; 2022; 9():839917. PubMed ID: 35402512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]